| Multiple Myeloma
Darzalex vs Mozobil
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Darzalex vs Mozobil with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMozobil has a higher rate of injection site reactions vs Darzalex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mozobil but not Darzalex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Darzalex
Mozobil
At A Glance
IV infusion
Weekly to every 4 weeks
Anti-CD38 monoclonal antibody
SC injection
Once daily for up to 4 days
CXCR4 antagonist
Indications
- Multiple Myeloma
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
Dosing
Multiple Myeloma 16 mg/kg IV; dosing schedule varies by combination regimen: weekly for initial doses (6-9 doses), then every 2-3 weeks, then every 4 weeks until disease progression; pre-medicate with corticosteroids, antipyretics, and antihistamines before each infusion.
Lymphoma, Non-Hodgkin, Multiple Myeloma 0.24 mg/kg SC (or 20 mg fixed dose for patients <=83 kg) once daily approximately 11 hours prior to apheresis for up to 4 consecutive days, following filgrastim 10 mcg/kg once daily for 4 days; maximum 40 mg/day.
Renal Impairment (CrCl <=50 mL/min) Reduce dose by one-third to 0.16 mg/kg SC (or 13 mg fixed dose for patients <=83 kg); maximum 27 mg/day.
Contraindications
- History of severe hypersensitivity (e.g., anaphylactic reactions) to daratumumab or any of the formulation components
- History of hypersensitivity to plerixafor
Adverse Reactions
Most common (>=20%) Upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, asthenia
Serious Pneumonia, infusion-related reactions (Grade 3-4), neutropenia, thrombocytopenia, febrile neutropenia, sepsis
Postmarketing Anaphylactic reaction, infusion-related reactions (including deaths), pancreatitis, cytomegalovirus, listeriosis
Most common (>=10%) Diarrhea, nausea, injection site reactions, fatigue, headache, arthralgia, dizziness, vomiting
Serious Anaphylactic shock, hypersensitivity reactions, tumor cell mobilization, hyperleukocytosis, decreased platelet counts, splenic enlargement
Postmarketing Splenomegaly, splenic rupture, anaphylactic reactions including anaphylactic shock, abnormal dreams and nightmares
Pharmacology
Anti-CD38 monoclonal antibody; daratumumab is an IgG1k human mAb that binds CD38 on tumor cells and induces apoptosis via Fc-mediated cross-linking and immune-mediated lysis through complement dependent cytotoxicity (CDC), antibody dependent cell mediated cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP).
Plerixafor is a CXCR4 chemokine receptor inhibitor that blocks binding of stromal cell-derived factor-1alpha (SDF-1alpha), disrupting HSC anchoring in the bone marrow and mobilizing hematopoietic stem cells to the peripheral blood for apheresis collection.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Darzalex
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Mozobil
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Darzalex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Mozobil
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Darzalex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Mozobil
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Acute Lymphoblastic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Chemotherapy Induced Neutropenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DarzalexView full Darzalex profile
MozobilView full Mozobil profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.